Evidence map›Paper›PMID 31383013›Full record

ArticleStem cell research & therapy2019

The effect of culture media on large-scale expansion and characteristic of adipose tissue-derived mesenchymal stromal cells.

Justyna Czapla, Sybilla Matuszczak, Klaudia Kulik, Ewa Wiśniewska, Ewelina Pilny, Magdalena Jarosz-Biej, Ryszard Smolarczyk, Tomasz Sirek, Michał Oskar Zembala, Marian Zembala and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Justyna CzaplaCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15 Street, 44-102, Gliwice, Poland.
Sybilla MatuszczakCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15 Street, 44-102, Gliwice, Poland.
Klaudia KulikCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15 Street, 44-102, Gliwice, Poland.
Ewa WiśniewskaKardio-Med Silesia, Maria Skłodowska-Curie 10C Street, 41-800, Zabrze, Poland.
Ewelina PilnyCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15 Street, 44-102, Gliwice, Poland.
Magdalena Jarosz-BiejCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15 Street, 44-102, Gliwice, Poland.
Ryszard SmolarczykCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15 Street, 44-102, Gliwice, Poland.
Tomasz SirekHospital for Minimally Invasive and Reconstructive Surgery, Armii Krajowej 180 Street, 43-316, Bielsko-Biała, Poland.
Michał Oskar ZembalaDepartment of Cardiac Surgery and Transplantology, Silesian Centre for Heart Diseases, Maria Curie Skłodowska 9 Street, 41-800, Zabrze, Poland.
Marian ZembalaDepartment of Cardiac Surgery and Transplantology, Silesian Centre for Heart Diseases, Maria Curie Skłodowska 9 Street, 41-800, Zabrze, Poland.
Stanisław SzalaCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15 Street, 44-102, Gliwice, Poland.
Tomasz CichońCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15 Street, 44-102, Gliwice, Poland. tomasz.cichon@io.gliwice.pl.ORCID 0000-0002-3009-7080
Kardio-Med Silesia · PLSilesian Center for Heart Disease · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdipose tissue-derived mesenchymal stromal cells (ASCs) have been shown to exhibit some promising properties of their use in regenerative medicine as advanced therapy medicinal products (ATMP). However, different sources of their origin, methods of isolation, and expansion procedures cause the laboratory and clinical results difficult to compare.

methodsASCs were isolated from lipoaspirates and cultured in three different medium formulations: αMEM and DMEM as a basal medium supplemented with 10% of human platelet lysate (hPL) and DMEM supplemented with 20% fetal bovine serum (FBS) and bFGF as a gold standard medium. Subsequently, the impact of culture media on ASCs growth kinetics, their morphology and immunophenotype, ability to differentiate, clonogenic potential, and secretion profile was evaluated.

resultsAll cultured ASCs lines showed similar morphology and similar clonogenic potential and have the ability to differentiate into three lines: adipocytes, osteoblasts, and chondroblasts. The immunophenotype of all cultured ASCs was consistent with the guidelines of the International Society for Cell Therapy (ISCT) allowing to define cells as mesenchymal stromal cell (MSC) (≥ 95% CD105, CD73, CD90 and ≤ 2% CD45, CD34, CD14, CD19, HLA-DR). The immunophenotype stabilized after the second passage and did not differ between ASCs cultured in different conditions. The exception was the ASCs grown in the presence of FBS and bFGF, which expressed CD146 antigens. The secretion profile of ASCs cultured in different media was similar. The main secreted cytokine was IL-6, and its level was donor-specific. However, we observed a strong influence of the medium formulation on ASCs growth kinetics. The proliferation rate of ASCs in medium supplemented with hPL was the highest.

conclusionsCulture media that do not contain animal-derived antigens (xeno-free) can be used to culture cells defined as MSC. Xeno-free medium is a safe alternative for the production of clinical-grade MSC as an advanced therapy medicinal product. Additionally, in such culture conditions, MSC can be easily expanded in accordance with the Good Manufacturing Process (GMP) requirements to a desired amount of cells for clinical applications.

Indexed as

AdipogenesisAdipose TissueAdultCD146 AntigenCell DifferentiationCell ProliferationCells, CulturedChondrogenesisCulture MediaFemaleFibroblast Growth Factor 2HumansImmunophenotypingInterleukin-6Mesenchymal Stem CellsMiddle AgedCD146 AntigenCulture MediaFibroblast Growth Factor 2Interleukin-6Adipose tissue-derived mesenchymal stromal cellsAdvanced therapy medicinal productsHuman platelet lysateInterleukin-6

Identifiers

PMID31383013
PMCPMC6683465
OpenAlexW2964844776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.